Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
|Articles|November 1, 2003
Tech-savvy Physicians Risk Violating Copyright Law
Author(s)David J. Goldberg, MD, JD
Dr. J considers himself a technologically savvy dermatologist. He has always had the latest computer and is always seen with a personal digital assistant (PDA).
Advertisement
Advertisement
Related to this article
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Revises TB Evaluation Guidance for SKYRIZI
2
Biologics, JAK Inhibitors, and Atopic March Data in Pediatric Atopic Dermatitis
3
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
4
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
5